10月5日，Kodiak Sciences盘中下跌5.09%，报89.65美元/股。
此次回调或源于前期利好因素逐渐兑现，参考信息显示公司于9月28日曾公布其两款眼科新药Zenkuda和tabirafusp-ted的三期试验达主要终点，导致当日股价大涨172%，同时董事Felix J. Baker于9月28-29日期间在79-90美元价格区间累计增持约35.9万股（基于Form 4披露）。基准研究/眼科学数据披露后获利盘回吐压力显现。
Kodiak Sciences Inc.是一家临床阶段的生物制药公司，专门研究治疗慢性高流行性视网膜疾病的新疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.